accréditation et d " évaluation en santé. Indications de l " épuration extra-rénale dans l " insuffisance rénale chronique terminale, 1996. ,
Diabète et Dialyse Péritonéale : Quelles spécificités ?, 2011. ,
Hémodialyse : principes généraux et modalités de traitement, MT Médecine-Thérapeutique, vol.4, pp.557-66, 1998. ,
The influence of dialysis treatment modality on the decline of remaining renal function, ASAIO Trans Am Soc Artif Intern Organs, vol.37, pp.598-604, 1991. ,
Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment, American Journal of Kidney Diseases, vol.29, issue.4, pp.584-92, 1997. ,
DOI : 10.1016/S0272-6386(97)90342-5
Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy???a Spanish multicentre experience, Nephrology Dialysis Transplantation, vol.21, issue.suppl_2, pp.51-56, 2006. ,
DOI : 10.1093/ndt/gfl191
Integrated care for ESRD patients, 1999. ,
La prise en charge du sujet âgé en dialyse péritonéale : le paradoxe français, 2011. ,
Physiopathologie de la membrane péritonéale. Actual. Néphrologiques Jean Hambg, Necker 2005. Flammarion médecine sciences, 2005. ,
Ultra-Filtration en Dialyse péritonéale, 2008. ,
A three-pore model of peritoneal transport, Perit Dial Int J Int Soc Perit Dial, vol.13, issue.2, pp.35-43, 1993. ,
Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis, Kidney International, vol.69, issue.9, pp.1518-1543, 2006. ,
DOI : 10.1038/sj.ki.5000285
Future of icodextrin as an osmotic agent in peritoneal dialysis, Kidney International, vol.62, pp.80-87, 2002. ,
DOI : 10.1046/j.1523-1755.62.s81.11.x
Peritoneal equilibration test with conventional ???low pH/high glucose degradation product??? or with biocompatible ???normal pH/low glucose degradation product??? dialysates: does it matter?, Nephrology Dialysis Transplantation, vol.13, issue.Suppl 4, pp.1946-51, 2013. ,
DOI : 10.1152/ajpheart.01364.2005
Dialyse péritonéale chez l " adulte : quel type pour quel patient ? ,
Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis, Kidney International, vol.69, issue.9, pp.1518-1543, 2006. ,
DOI : 10.1038/sj.ki.5000285
Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group, Nephrology Dialysis Transplantation, vol.17, issue.Suppl_2, pp.2052-62, 2010. ,
DOI : 10.1046/j.1523-1755.1998.00010.x
Fresenius Medical care. Utilisation des plastifiants dans le traitement par dialyse, Bull Dial Péritonéale, vol.7, 1997. ,
History, chemical and pharmaceutical development of icodextrin, Perit Dial, vol.14, pp.5-12, 1994. ,
A randomized multicenter clinical trial comparing isosmolar Icodextrin with hyperosmolar glucose solutions in CAPD, Kidney International, vol.46, issue.2, pp.496-503, 1994. ,
DOI : 10.1038/ki.1994.300
Glycation and advanced glycation end-product formation with icodextrin and dextrose, Perit Dial Int J Int Soc Perit Dial, vol.17, pp.52-60, 1997. ,
Cost-Containment in CAPD Patients with Ultrafiltration Failure, Clinical Drug Investigation, vol.10, issue.1, pp.53-61, 1995. ,
DOI : 10.2165/00044011-199510010-00009
Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance, Nephrology Dialysis Transplantation, vol.12, issue.3, pp.550-553, 1997. ,
DOI : 10.1093/ndt/12.3.550
Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD, Kidney International, vol.57, issue.6, pp.2546-56, 2000. ,
DOI : 10.1046/j.1523-1755.2000.00114.x
Peritoneal transport in peritoneal dialysis patients using glucose-based and amino acidbased solutions, Perit Dial Int J Int Soc Perit Dial, vol.27, pp.544-53, 2007. ,
Peritoneal transport kinetics with amino acid-based and glucosebased peritoneal dialysis solutions, Perit Dial Int J Int Soc Perit Dial, vol.27, pp.518-540, 2007. ,
Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution, The Lancet, vol.365, issue.9459, pp.588-94, 2005. ,
DOI : 10.1016/S0140-6736(05)70800-X
Aseptic peritonitis due to peptidoglycan, The Lancet, vol.366, issue.9482, pp.289-90, 2005. ,
DOI : 10.1016/S0140-6736(05)66976-0
Rapport annuel REIN, 2011. ,
Indications et non-indications de la dialyse péritonéale chronique chez l " adulte. HAS, 2007. ,
APD schedules and clinical results, Contrib Nephrol, pp.272-279, 2003. ,
DOI : 10.1159/000093622
Information relative au dispoditif médical UV Flash Compact, 2014. ,
Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group, J Am Soc Nephrol JASN, vol.8, pp.965-71, 1997. ,
Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial, Clinical Journal of the American Society of Nephrology, vol.3, issue.2, pp.407-422, 2008. ,
DOI : 10.2215/CJN.03820907
Predictors of the rate of decline of residual renal function in incident dialysis patients, Kidney International, vol.62, issue.3, pp.1046-53, 2002. ,
DOI : 10.1046/j.1523-1755.2002.00505.x
Actualit??s en??dialyse p??riton??ale, La Presse M??dicale, vol.36, issue.12, pp.1823-1831, 2007. ,
DOI : 10.1016/j.lpm.2007.04.038
The importance of residual renal function in dialysis patients, Kidney International, vol.69, issue.10, pp.1726-1758, 2006. ,
DOI : 10.1038/sj.ki.5000382
Benefits of preserving residual renal function in peritoneal dialysis, Kidney International, vol.73, 2008. ,
DOI : 10.1038/sj.ki.5002600
Effect of fluid and sodium removal on mortality in peritoneal dialysis patients, Kidney International, vol.60, issue.2, pp.767-76, 2001. ,
DOI : 10.1046/j.1523-1755.2001.060002767.x
Survival of Functionally Anuric Patients on Automated Peritoneal Dialysis: The European APD Outcome Study, Journal of the American Society of Nephrology, vol.14, issue.11, pp.2948-57, 2003. ,
DOI : 10.1097/01.ASN.0000092146.67909.E2
European best practice guidelines for peritoneal dialysis Adequacy of peritoneal dialysis, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.20, pp.24-31, 2005. ,
Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy, Perit Dial Int J Int Soc Perit Dial, vol.31, pp.218-257, 2011. ,
PERITONEAL DIALYSIS-RELATED INFECTIONS RECOMMENDATIONS: 2010 UPDATE, Peritoneal Dialysis International, vol.30, issue.4, pp.393-423, 2010. ,
DOI : 10.3747/pdi.2010.00049
URL : http://www.pdiconnect.com/content/30/4/393.full.pdf
La scl??rose p??riton??ale encapsulante??: aspects actuels, N??phrologie & Th??rapeutique, vol.5, issue.2, pp.122-155, 2009. ,
DOI : 10.1016/j.nephro.2008.08.014
Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis, J Am Soc Nephrol JASN, vol.12, pp.1046-51, 2001. ,
Peritoneal dialysis solution biocompatibility testing in animals, Perit Dial Int J Int Soc Perit Dial, vol.15, pp.61-70, 1995. ,
Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain, Kidney International, vol.53, issue.4, pp.1061-1068, 1998. ,
DOI : 10.1111/j.1523-1755.1998.00849.x
Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution, Perit Dial Int J Int Soc Perit Dial, vol.23, pp.138-183, 2003. ,
The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane, Kidney International, vol.66, issue.1, pp.408-426, 2004. ,
DOI : 10.1111/j.1523-1755.2004.00747.x
lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels, Kidney Int, vol.59, pp.1529-1567, 2001. ,
Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucosedegradation products--a 1-year randomized control trial, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.22, pp.552-561, 2007. ,
Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane, Kidney International, vol.66, issue.3, pp.1257-65, 2004. ,
DOI : 10.1111/j.1523-1755.2004.00879.x
Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution, J Am Soc Nephrol JASN, vol.12, pp.2775-86, 2001. ,
Clinical indices of in vivo biocompatibility: The role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients, Kidney International, vol.64, pp.84-93, 2003. ,
DOI : 10.1046/j.1523-1755.2003.08809.x
Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance), Perit Dial Int J Int Soc Perit Dial, vol.25, pp.248-55, 2005. ,
Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis, Nephrology Dialysis Transplantation, vol.22, issue.6, pp.1703-1711, 2007. ,
DOI : 10.1093/ndt/gfl848
Mortality and Technique Failure in Peritoneal Dialysis Patients Using Advanced Peritoneal Dialysis Solutions, American Journal of Kidney Diseases, vol.54, issue.4, pp.711-731, 2009. ,
DOI : 10.1053/j.ajkd.2009.05.014
Effects of Biocompatible versus Standard Fluid on Peritoneal Dialysis Outcomes, Journal of the American Society of Nephrology, vol.23, issue.6, pp.1097-107, 2012. ,
DOI : 10.1681/ASN.2011121201
Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study, Nephrology Dialysis Transplantation, vol.41, issue.6, pp.2899-908, 2009. ,
DOI : 10.1016/S0272-6386(03)00353-6
Low-GDP fluid (Gambrosol trio(R)) attenuates decline of residual renal function in PD patients: a prospective randomized study, Nephrology Dialysis Transplantation, vol.21, issue.10, pp.2288-96, 2010. ,
DOI : 10.1681/ASN.2005020155
Benefit of Glucose-Free Dialysis Solutions on Glucose and Lipid Metabolism in Peritoneal Dialysis Patients, Blood Purification, vol.258, issue.4, pp.303-313, 2005. ,
DOI : 10.1016/S0140-6736(63)91500-9
Effect of an l-Carnitine???Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial, American Journal of Kidney Diseases, vol.62, issue.5, pp.929-967, 2013. ,
DOI : 10.1053/j.ajkd.2013.04.007
l-Carnitine is an osmotic agent suitable for peritoneal dialysis, Kidney International, vol.80, issue.6, pp.645-54, 2011. ,
DOI : 10.1038/ki.2011.117
URL : https://doi.org/10.1038/ki.2011.117
Hyperbranched Polyglycerol: A Future Alternative to Polyglucose in Peritoneal Dialysis Fluids?, Peritoneal Dialysis International, vol.33, issue.1, pp.5-7, 2013. ,
DOI : 10.3747/pdi.2012.00317
Hyperbranched Polyglycerol Is an Efficacious and Biocompatible Novel Osmotic Agent in a Rodent Model of Peritoneal Dialysis, Peritoneal Dialysis International, vol.33, issue.1, pp.15-27, 2013. ,
DOI : 10.3747/pdi.2012.00148
Bimodal Solutions or Twice-Daily Icodextrin to Enhance Ultrafiltration in Peritoneal Dialysis Patients, International Journal of Nephrology, vol.31, issue.2, pp.424915-424925, 2013. ,
DOI : 10.1111/j.1440-1797.2009.01186.x
Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell, Perit Dial Int J Int Soc Perit Dial, vol.27, pp.267-76, 2007. ,
Randomized, Controlled Trial of Glucose-Sparing Peritoneal Dialysis in Diabetic Patients, Journal of the American Society of Nephrology, vol.24, issue.11, pp.1889-900, 2013. ,
DOI : 10.1681/ASN.2012100987
THE BENEFICIAL INFLUENCE ON THE EFFECTIVENESS OF AUTOMATED PERITONEAL DIALYSIS OF VARYING THE DWELL TIME (SHORT/LONG) AND FILL VOLUME (SMALL/LARGE): A RANDOMIZED CONTROLLED TRIAL, Peritoneal Dialysis International, vol.31, issue.4, pp.450-458, 2011. ,
DOI : 10.3747/pdi.2010.00146
o\U: U' I: r i\T DE llOCTEUM r.N PItAR. \ IAC IE ,
12 SEI'. ZlH Do)a ... Il F~. l'loo " 1.01'11" dt l'UIIi ,